Tag Archives: endovascular treatment

Device Effectiveness for Femoropopliteal Artery Disease Treatment: Analysis of K-VIS ELLA Registry

Device Effectiveness for Femoropopliteal Artery Disease Treatment: Analysis of K-VIS ELLA Registry

Endovascular treatment of lesions in femoropopliteal territory (FPA) has become the main therapeutic option, seeing as it is less invasive and has faster recovery. It has used different devices, such as conventional bare metal stents (BMS), balloon angioplasty (POBA), and drug coated balloons (DCB), as well as drug eluting stents (DES). However, real world data

Un guiño para la trombólisis guiada por Catéter en tromboembolismo pulmonar

CLOUT Registry: Thrombectomy in TVP with ClotTriever

Safety and efficacy of the ClotTriever device in extended deep vein thrombosis.  The endovascular treatment of thromboembolic disease has evolved and new devices have come out in the last few years to reduce morbimortality from its complications. Sub-treating this pathology has long term implications, such as reduced quality of life, limiting functional class and, worst

Resultados alentadores de los balones cubiertos de Biolimus para el tratamiento de vasos pequeños

Drug Coated Balloons in Femoropopliteal Territory: Predictors of Failed Patency

Endovascular treatment in femoropopliteal territory has become the strategy of choice over time, with diverse devices; among others, drug coated balloons (DCB). DBS are meant to provide the antiproliferation effect of drugs while reducing exposure of a specific artery segment to a strange body.   Even though the number of studies on DCB effectiveness has been

DISRUPT-PAD III: Seguimiento del tratamiento con IVL en territorio femoropoplíteo

DISRUPT-PAD III: Followup of IVL Treatment in Femoropopliteal Territory

Femoropopliteal segment calcification can generate complications for both preparation and execution of endovascular therapies for patients with peripheral artery disease. It can produce suboptimal vessel expansion associated to higher risk of dissection or perforation. These adverse effects can affect procedure durability in the long term.  Studies on the use of drug coated balloons to treat

EuroPCR 2022

EuroPCR 2022 | CLASP TR Study: Promising Results of Endovascular Intervention of Tricuspid Regurgitation

At present, we are well aware of the rise in mortality caused by severe tricuspid regurgitation (TR). Medical and surgical treatments have turned out to be suboptimal. Hence, endovascular intervention presents as an alternative therapeutic strategy with promising results.  The aim of this multicenter, prospective study was to assess the safety and efficacy of the

El tratamiento endovascular parece superior a la cirugía en aneurismas rotos

Abdominal Aortic Aneurysm during the Pandemic: Should They Be Operated or Deferred?

Some European societies have recommended deferring the treatment of infrarenal abdominal aortic aneurysm (AAA) ≥5.5 cm during the COVID-19 pandemic. However, these documents have also suggested optimal deferral times, and everything must be adjusted according to the transmission risk/risk of rupture balance. Annual risk of rupture can be estimated based on a prospective cohort published by

Evaluación Hemodinámica de la Insuficiencia Aórtica post TAVR

Medical vs. Endovascular Treatment in Uncomplicated Type B Aortic Dissection

Under much debate, the treatment of uncomplicated type B aortic dissection is still uncertain. Several studies with methodological limitations have shown that endovascular treatment plus optimal medical treatment might be beneficial, compared with medical treatment alone. This meta-analysis sought to define more clearly the treatment strategy in patients with acute and subacute uncomplicated type B

¿Beneficio adicional del bypass radial en la cirugía de revascularización miocárdica?

Infrainguinal Bypass Following Failed Endovascular Intervention Has a Different Outcome

We often inform our patients we should first approach the superficial femoral with an endovascular intervention, and that should it fail or develop restenosis, we could always resort to a bypass. We were not lying when we’d assume a bypass following endovascular intervention would have the same outcome as a primary bypass. Simply put, no

Stent directo vs angioplastia convencional y sus interacciones con la trombo-aspiración

Bioresorbable scaffolds with drug-eluting stents: do they entail a higher thrombosis risk?

Courtesy of Dr. Leiva. Bioresorbable scaffolds with drug-eluting stents (bioresorbable vascular scaffolds, BVS) have been added to the list of endovascular treatment options for coronary disease. The ABSORB III trial showed the non-inferiority of this stent type to everolimus-eluting metallic stents as regards target-lesion revascularization (TLR) at one year. However, reports have suggested a higher

Las ondas venosas pulmonares en el MitraClip tienen valor pronóstico

MitraClip Similar to Surgery at 5 Years

Original Title: Randomized Comparison of Percutaneous Repair and Surgery for Mitral Regurgitation. 5 – Years Results of EVEREST II. Reference: Ted Feldman et al. J Am Coll Cardiol 2015;66:2844-54 Courtesy of Dr. Carlos Fava The MitraClip at 12 months in the EVEREST II trial showed similar outcomes to that of surgery, with improved ventricular remodeling and

Top